Stéphane Pion
Direttore/Membro del Consiglio presso PainCeptor Pharma Corp.
Profilo
Dr. Pion holds a Ph.D.
degree in Immunology from the Université de Montréal, having conducted his doctorate studies at the Maisonneuve-Rosemont Hospital.
He joined T2C2/Bio in 1998 and is very active in the domain of information technology.
Posizioni attive di Stéphane Pion
| Società | Posizione | Inizio |
|---|---|---|
PainCeptor Pharma Corp.
 PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Stéphane Pion
| Società | Posizione | Fine |
|---|---|---|
Transfer Technologies Commercialisation Capital
 Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Analista di Private Equity | - |
Formazione di Stéphane Pion
| University of Montréal | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
- Borsa valori
- Insiders
- Stéphane Pion
